Inspire Medical Systems, Inc. $INSP Shares Bought by Quantinno Capital Management LP

Quantinno Capital Management LP grew its stake in Inspire Medical Systems, Inc. (NYSE:INSP) by 103.5% during the 1st quarter, HoldingsChannel reports. The firm owned 26,555 shares of the company’s stock after buying an additional 13,507 shares during the quarter. Quantinno Capital Management LP’s holdings in Inspire Medical Systems were worth $1,370,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Wellington Management Group LLP acquired a new stake in Inspire Medical Systems during the fourth quarter valued at $203,929,000. Wasatch Advisors LP grew its position in shares of Inspire Medical Systems by 7.2% during the 2nd quarter. Wasatch Advisors LP now owns 1,634,395 shares of the company’s stock valued at $212,095,000 after acquiring an additional 110,288 shares during the period. Morgan Stanley increased its stake in shares of Inspire Medical Systems by 179.5% in the 4th quarter. Morgan Stanley now owns 1,259,762 shares of the company’s stock valued at $116,188,000 after purchasing an additional 809,121 shares in the last quarter. Deerfield Management Company L.P. raised its holdings in Inspire Medical Systems by 648.4% in the 3rd quarter. Deerfield Management Company L.P. now owns 1,047,694 shares of the company’s stock worth $77,739,000 after purchasing an additional 907,694 shares during the period. Finally, State Street Corp boosted its position in Inspire Medical Systems by 2.3% during the second quarter. State Street Corp now owns 1,030,902 shares of the company’s stock worth $133,780,000 after purchasing an additional 22,843 shares in the last quarter. 94.91% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have recently commented on INSP shares. Freedom Capital upgraded Inspire Medical Systems to a “strong-buy” rating in a research report on Tuesday, June 30th. Truist Financial restated a “hold” rating and set a $62.00 price objective (up from $54.00) on shares of Inspire Medical Systems in a research report on Tuesday, August 4th. JPMorgan Chase & Co. lifted their target price on shares of Inspire Medical Systems from $54.00 to $60.00 and gave the company a “neutral” rating in a research report on Tuesday, August 4th. Royal Bank Of Canada restated a “sector perform” rating and set a $60.00 price target on shares of Inspire Medical Systems in a research report on Tuesday, August 4th. Finally, KeyCorp reiterated a “sector weight” rating on shares of Inspire Medical Systems in a report on Tuesday, August 4th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, thirteen have assigned a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $68.00.

Inspire Medical Systems Stock Performance

NYSE:INSP opened at $58.24 on Friday. Inspire Medical Systems, Inc. has a one year low of $38.91 and a one year high of $147.03. The stock has a market cap of $1.68 billion, a PE ratio of 12.61, a P/E/G ratio of 4.43 and a beta of 0.70. The stock has a 50 day moving average price of $49.06 and a 200 day moving average price of $53.44.

Inspire Medical Systems (NYSE:INSP) last released its quarterly earnings data on Monday, August 3rd. The company reported $0.14 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.38. The company had revenue of $200.58 million for the quarter, compared to analyst estimates of $194.72 million. Inspire Medical Systems had a return on equity of 8.64% and a net margin of 15.03%.During the same quarter in the previous year, the company posted $0.45 earnings per share. The firm’s revenue for the quarter was down 7.6% compared to the same quarter last year. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. As a group, analysts predict that Inspire Medical Systems, Inc. will post 1.24 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Jason P. Kelly sold 963 shares of the company’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $59.55, for a total value of $57,346.65. Following the completion of the sale, the insider owned 18,985 shares of the company’s stock, valued at approximately $1,130,556.75. This represents a 4.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 2.20% of the company’s stock.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.